Extrahepatic manifestations of chronic hepatitis C, Arthritis & Rheumatism, vol.59, issue.10, pp.2204-2216, 1999. ,
DOI : 10.1159/000007517
URL : https://hal.archives-ouvertes.fr/hal-01159323
Extrahepatic manifestations of chronic hepatitis C virus infection, Therapeutic Advances in Infectious Disease, vol.15, issue.3, pp.3-14, 2016. ,
DOI : 10.1038/gene.2014.41
URL : https://hal.archives-ouvertes.fr/hal-01159323
Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach, Digestive and Liver Disease, vol.39, issue.1, pp.2-17, 2007. ,
DOI : 10.1016/j.dld.2006.06.008
Extrahepatic manifestations of chronic hepatitis C virus infection, Digestive and Liver Disease, vol.46, pp.165-173, 2014. ,
DOI : 10.1016/j.dld.2014.10.005
URL : https://hal.archives-ouvertes.fr/hal-01159323
HCV syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin???s lymphoma, and cancer, World Journal of Hepatology, vol.7, issue.3, pp.327-370, 2015. ,
DOI : 10.1182/blood-2009-10-245878
Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China, Chin Med J (Engl), vol.127, pp.1206-1216, 2014. ,
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in??patients with chronic hepatitis C virus genotype 1 infection, Alimentary Pharmacology & Therapeutics, vol.27, issue.Suppl 1, pp.544-63, 2015. ,
DOI : 10.1111/j.1440-1746.2011.06813.x
Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C, Expert Review of Pharmacoeconomics & Outcomes Research, vol.7, issue.10, pp.659-665, 2016. ,
DOI : 10.3748/WJG.v22.i35.8050
Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients, Journal of Hepatology, vol.60, issue.3, pp.530-537, 2014. ,
DOI : 10.1016/j.jhep.2013.11.009
How did chronic hepatitis C impact costs related to hospital health care in France, Clin Res Hepatol Gastroenterol, 2009. ,
DOI : 10.1016/j.clinre.2012.11.004
Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of??Prevalence, Quality of Life, and Economic Burden, Gastroenterology, vol.150, issue.7, pp.1599-608, 2016. ,
DOI : 10.1053/j.gastro.2016.02.039
Estimation de la prévalence de l'hépatite C en population générale, France métropolitaine, Bull Epidémiol Hebd, pp.13-14224, 2011. ,
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia, Hepatology, vol.27, issue.Suppl. 13, pp.1473-8214, 2016. ,
DOI : 10.1038/leu.2012.238
Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents, Hepatology, vol.310, issue.2, pp.408-425, 2016. ,
DOI : 10.1001/jama.2013.109309
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study, Annals of the Rheumatic Diseases, vol.11, issue.(1 Pt 1), pp.1777-82, 2016. ,
DOI : 10.1016/j.autrev.2011.07.005
Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C, Journal of Hepatology, vol.36, issue.6, pp.812-820, 2002. ,
DOI : 10.1016/S0168-8278(02)00067-3
Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients, Hepatology, vol.359, issue.Suppl 1, pp.1293-302, 2014. ,
DOI : 10.1016/S0140-6736(02)07339-7
Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection, Gut, vol.59, issue.3, pp.495-503, 2015. ,
DOI : 10.1016/j.jclinepi.2006.07.002
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3, Gut, vol.61, issue.1, pp.128-162, 2012. ,
DOI : 10.1136/gut.2010.236158
Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs, New England Journal of Medicine, vol.373, issue.27, pp.2678-80, 2015. ,
DOI : 10.1056/NEJMe1513245
Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study), Clinics and Research in Hepatology and Gastroenterology, vol.40, issue.3, pp.340-348, 2016. ,
DOI : 10.1016/j.clinre.2015.08.006
The case for cost-effectively treating cryoglobulinemic vasculitis with interferon-free anti-hepatitis C virus therapy, Hepatology, vol.60, issue.3, p.975, 2015. ,
DOI : 10.1002/hep.27151
A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C, Clinical Gastroenterology and Hepatology, vol.9, issue.6, pp.509-525, 2011. ,
DOI : 10.1016/j.cgh.2011.03.004
Effectiveness and cost of hepatitis C virus cryoglobulinemia vasculitis treatment: from interferon-based to direct-acting antivirals, Liver Int ,
URL : https://hal.archives-ouvertes.fr/hal-01521117
Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in the United States, The Journal of Rheumatology, vol.42, issue.12, pp.2383-91, 2015. ,
DOI : 10.3899/jrheum.150479
Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study, Journal of Infectious Diseases, vol.206, issue.4, pp.469-77, 2012. ,
DOI : 10.1093/infdis/jis385
URL : https://academic.oup.com/jid/article-pdf/206/4/469/2571090/jis385.pdf